Harvard Bioscience Reports Q1 2026 Revenue Dip but Margin Expansion
Event summary
- Q1 2026 revenue of $20.8M, down from $21.8M in Q1 2025.
- Gross margin improved to 59% from 56% year-over-year.
- Adjusted EBITDA remained flat at $0.8M, with net loss narrowing to $(3.4)M from $(50.3)M in Q1 2025.
- Manufacturing consolidation on track, expected to yield cost savings.
- Reaffirmed full-year 2026 guidance, anticipating high-margin NPI sales growth.
The big picture
Harvard Bioscience is focusing on operational efficiency and higher-margin product adoption to drive growth. The company's strategic shift toward a higher-margin product mix, particularly in the biopharma sector, is expected to put it on a path toward consistent 60%+ margins and higher recurring revenue. The manufacturing consolidation is a key initiative aimed at achieving significant cost savings and operational efficiencies.
What we're watching
- Product Adoption
- How the adoption rates of the MeshMEA™ organoid platform, BTX® Electroporation, and SoHo™ Telemetry systems will impact the shift toward a higher-margin product mix.
- Operational Efficiency
- The pace at which manufacturing consolidation will yield significant efficiencies and cost savings.
- Financial Guidance
- Whether the company can sustain the anticipated high-margin NPI sales growth to drive bottom-line growth in the second half of the year.
Related topics